Translational Medicine Center, Honghui Hospital, Xi'an Jiaotong University, Xi'an 710054, China.
Translational Medicine Center, Honghui Hospital, Xi'an Jiaotong University, Xi'an 710054, China.
Int Immunopharmacol. 2019 Jul;72:258-263. doi: 10.1016/j.intimp.2019.04.023. Epub 2019 Apr 16.
The classical renin-angiotensin system (RAS) is known to be a key regulator of blood pressure as well as fluid and electrolyte homeostasis. Additionally, it is now evident that components of the RAS are produced and act locally in many tissues, including liver, kidney, heart, lung, eye, bone, reproductive organ, adipose, and adrenal tissue, and these components are collectively known as tissue RAS. Recently, several studies have shown that local bone RAS is directly involved in bone metabolism, and activation of skeletal RAS plays an important role in bone diseases, such as osteoporosis, arthritis, and deterioration as well as in fracture healing. Based on the identification of RAS components in bone, we examined a new therapeutic approach to attenuate bone diseases through RAS inhibitors: renin inhibitor, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers. In this paper, we provide a systematic review of the skeletal RAS in the pathophysiology of bone diseases and the beneficial effect of RAS inhibitors on bone tissue.
经典的肾素-血管紧张素系统（RAS）是众所周知的血压以及液体和电解质稳态的关键调节剂。此外，现在很明显，RAS 的成分在许多组织中产生并局部发挥作用，包括肝、肾、心脏、肺、眼、骨、生殖器官、脂肪组织和肾上腺组织，这些成分统称为组织 RAS。最近，几项研究表明，局部骨骼 RAS 直接参与骨代谢，骨骼 RAS 的激活在骨疾病（如骨质疏松症、关节炎和恶化以及骨折愈合）中起着重要作用。基于在骨骼中鉴定出 RAS 成分，我们研究了通过 RAS 抑制剂减轻骨骼疾病的新治疗方法：肾素抑制剂、血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂。在本文中，我们对骨骼 RAS 在骨骼疾病的病理生理学中的作用以及 RAS 抑制剂对骨骼组织的有益作用进行了系统综述。
